Attention deficit hyperactivity disorder (ADHD) is a condition that affects people’s behaviour. People with ADHD can seem restless, may have trouble concentrating and may act on impulse.
This will be a Phase II clinical trial for lysergic acid diethylamide (LSD) in adult patients with ADHD evaluating the safety and efficacy of low-dose LSD as a treatment for ADHD in adults. This trial will use MindMed’s proprietary version of LSD, MM-120.
Maastricht University and the University of Basel will provide facilities and personnel for the Phase II Proof of Concept Clinical Trial for MindMed’s multicentre, randomized, double-blind, placebo-controlled trial.